HER2 0, HER2 1+and HER2 2+/FISH Negative Primary Breast Cancers Are Biologically Distinct

被引：0
|
作者：
Donahue, Nolan [1 ]
Aragao, Alessa [2 ]
Gordezky, Rachel [3 ]
Haddad, Sandra [1 ]
Tang, Ping [1 ]
机构：
[1] Loyola Univ Med Ctr, Maywood, IL 60153 USA
[2] Mayo Clin, Rochester, MN USA
[3] Loyola Pathol, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
122
引用
收藏
页码：S146 / S148
页数：3
相关论文
共 50 条
  • [1] HER2 0, HER2 1+and HER2 2+/FISH Negative Breast Cancers Are Biologically Different
    Mon, Khin Su
    Zhang, Hui
    Aragao, Alessa
    Tang, Ping
    LABORATORY INVESTIGATION, 2023, 103 (03) : S182 - S183
  • [2] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [3] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [4] Activating HER2 mutations in HER2 gene amplification negative breast cancers.
    Bose, R.
    Kavuri, S. M.
    Searleman, A. C.
    Shen, W.
    Shen, D.
    Koboldt, D. C.
    Monsey, J.
    Li, S.
    Ding, L.
    Mardis, E. R.
    Ellis, M. J.
    CANCER RESEARCH, 2012, 72
  • [5] Her2 FISH amplification in ER/PR/Her2 IHC negative breast cancer
    Sahoo, Sunati
    Hwang, Helena
    CANCER RESEARCH, 2015, 75
  • [6] HER2 or not HER2: That is the question
    Burstein, HJ
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3656 - 3659
  • [7] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [8] HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
    Li, Bob T.
    Ross, Dara S.
    Aisner, Dara L.
    Chaft, Jamie E.
    Hsu, Meier
    Kako, Severine L.
    Kris, Mark G.
    Varella-Garcia, Marileila
    Arcila, Maria E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) : 414 - 419
  • [9] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [10] Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification
    Lee, Andrew H. S.
    Key, Heather P.
    Bell, Jane A.
    Hodi, Zsolt
    Ellis, Ian O.
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (06) : 490 - 492
12345